Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Invesco S&P 500 Momentum ETF trades at $151.7. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | SPMO | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $18.70 | $161.66 |
52-Week Low | $7.64 | $107.84 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SPMO trades at $153.75, up 0.44% today, with a neutral technical signal. Momentum factor performance remains strong, gaining 7.5% in June 2026. The ETF's concentrated technology exposure (55%) drives returns but increases volatility. Support lies at $152, resistance at $155. Recent news highlights momentum's dominance in Q2 2026 with a 44.4% gain.
Outlook remains positive due to AI-driven momentum, though high sector concentration poses risks during market rotations. Analyst sentiment is generally bullish, but investors should monitor for signs of momentum fatigue or broader market pullbacks that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
